15644-80-1

Basic information

• Product Name: 2,8-DIMETHYL-4-HYDROXYQUINOLINE
• Synonyms: 2,8-DIMETHYL-4(1H)-QUINOLINONE;2,8-DIMETHYL-4-HYDROXYQUINOLINE;2,8-DIMETHYL-4-QUINOLINOL;2,8-DIMETHYLQUINOLIN-4(1H)-ONE;2,8-DIMETHYLQUINOLIN-4-OL;alsoCAS-No.52481-91-1;Nsc31466
• CAS NO: 15644-80-1
• Molecular Formula: C₁₁H₁₁NO
• Molecular Weight: 173.21
• Mol File: 15644-80-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 262.3°C
• Boiling Point: 303.86°C (rough estimate)
• Flash Point: 124.9 °C
• Appearance: /
• Density: 1.0898 (rough estimate)
• Vapor Pressure: 0.00184mmHg at 25°C
• Refractive Index: 1.4950 (estimate)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,8-DIMETHYL-4-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,8-DIMETHYL-4-HYDROXYQUINOLINE(15644-80-1)
• EPA Substance Registry System: 2,8-DIMETHYL-4-HYDROXYQUINOLINE(15644-80-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 15644-80-1(Hazardous Substances Data)

Usage

General Description

2,8-Dimethyl-4-hydroxyquinoline is a chemical compound with the molecular formula C11H13NO, and it is commonly referred to as DHQ. It is a compound that belongs to the class of quinoline derivatives, and it is often used in the manufacturing of pharmaceutical drugs and organic chemicals. 2,8-Dimethyl-4-hydroxyquinoline is known for its antioxidant properties and is used as an antioxidant in rubber and plastics. It is also used as a corrosion inhibitor and as a stabilizer in fuels. This chemical has potential applications in various industries due to its unique properties and versatile nature.

InChI:InChI=1/C11H11NO/c1-7-4-3-5-9-10(13)6-8(2)12-11(7)9/h3-6H,1-2H3,(H,12,13)

Upstream product

• 33240-19-6 ethyl (Z)-3-(o-tolylamino)but-2-enoate 
• 105-45-3 acetoacetic acid methyl ester 
• 95-53-4 o-toluidine 
• 33240-19-6 ethyl 3-[(2-methylphenyl)amino]but-2-enoate 
• 13562-88-4 2-ethylbutyl 3-oxobutanoate 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 49612-06-8 4-hydrazino-2,8-dimethylquinoline 
• 32314-39-9 4-chloro-2,8-dimethylquinoline 
• 34550-29-3 2,8-dimethyl-3-formyl-4-hydroxyquinoline 
• 503552-61-2 4-chloro-3-formyl-8-methyl-2-(2-hydroxy-ethen-1-yl)quinoline 
• 111947-00-3 (4-hydroxy-2,8-dimethyl-[3]quinolyl)-phenyl ketone 
• 1049804-72-9 2-methyl-6-(3-methyl-1H-pyrazol-5-yl)aniline 

Relevant articles and documents

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

N1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors

A series of N1-{4-[(10S)-dihydroartemisinin- 10-oxyl]}phenylmethylene-N2-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain- 2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, 1H NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 μM). The best one of this series was compound 9d (IC50 = 0.15 μM). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.

Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.